Cameron Firth

Macfarlanes

When it comes to big-scale, long-running pharmaceutical wrangles, Macfarlanes partner Cameron Firth has seen his fair share. Clients include Flynn Pharma and Teva in important backwards and forwards disputes over unfair price fixing, a massive battleground for competition law in the UK. Up against the Competition and Markets Authority, Firth has guided Flynn Pharma on several challenges to a fine handed down by the regulator, including the successful turnaround of a CMA decision that the company’s prices were an unlawful “abuse” of dominance. A trip to the Supreme Court is set for February over costs and whether they can recover them from the CMA.

Firth has plenty of in-court action scheduled for 2022, appealing for Teva (and its interests) over another unfair pricing fine handed down to a mega-pharma client. His competition nous is not simply isolated to pharma, though. He will defend cable company Prysmian Group in a follow-on damages claim this year, filed after the European Commission decided to fine several businesses for operating a cartel. For a firm that rarely makes lateral hires, Macfarlanes has been proven right in securing Firth and his top-notch competition practice.